Literature DB >> 12038878

Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Sandra S Kindermann1, Christian R Dolder, Anne Bailey, Ira R Katz, Dilip V Jeste.   

Abstract

A number of studies, using different research designs and assessment instruments, have been conducted to elucidate the differential effects of drug treatments for psychosis, agitation and aggression in elderly patients with dementia. We have reviewed literature published from 1960 to 2000 on this topic; 48 studies that met our selection criteria were identified from Medline and Science Citation Index. Antipsychotic medication was generally effective for the treatment of psychosis and agitation in elderly patients with dementia. In double-blind, placebo-controlled trials in this population, mean improvement rates were 61% with antipsychotics and 35% with placebo. Atypical antipsychotics appeared promising, but the number of well-designed studies has been small so far. Methodological limitations of the studies reviewed are discussed; future trials should ensure adequate sample size and duration and involve direct comparisons of individual medications. In conclusion, conventional antipsychotics are modestly effective for treatment of psychosis and agitation in elderly individuals with dementia, whereas newer treatments such as atypical antipsychotics appear to be at least as effective while having fewer adverse effects. Nonetheless, there is no currently available ideal pharmacotherapy, and psychosocial management is a necessary part of overall treatment. Additional large-scale, well-controlled studies are needed before conclusive statements regarding the value of treatment of psychosis and agitation with atypical antipsychotics and non-antipsychotic agents can be made.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12038878     DOI: 10.2165/00002512-200219040-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  116 in total

1.  Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease.

Authors:  L E Tune; C Steele; T Cooper
Journal:  Psychiatr Clin North Am       Date:  1991-06

2.  Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.

Authors:  D V Jeste; A Okamoto; J Napolitano; J M Kane; R A Martinez
Journal:  Am J Psychiatry       Date:  2000-07       Impact factor: 18.112

3.  Behavioral effects of drug therapy on psychogeriatric inpatients. I. Chlorpromazine and thioridazine.

Authors:  H Altman; D Mehta; R C Evenson; I W Sletten
Journal:  J Am Geriatr Soc       Date:  1973-06       Impact factor: 5.562

4.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.

Authors:  C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

Review 5.  Large-scale randomized evidence: large, simple trials and overviews of trials.

Authors:  R Peto; R Collins; R Gray
Journal:  J Clin Epidemiol       Date:  1995-01       Impact factor: 6.437

6.  Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances.

Authors:  I B Frenchman; T Prince
Journal:  Int Psychogeriatr       Date:  1997-12       Impact factor: 3.878

7.  A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

Authors:  P N Tariot; P R Solomon; J C Morris; P Kershaw; S Lilienfeld; C Ding
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

8.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Authors:  J S Street; W S Clark; K S Gannon; J L Cummings; F P Bymaster; R N Tamura; S J Mitan; D L Kadam; T M Sanger; P D Feldman; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-10

Review 9.  Anticonvulsant and other non-neuroleptic treatment of agitation in dementia.

Authors:  P N Tariot; L S Schneider; I R Katz
Journal:  J Geriatr Psychiatry Neurol       Date:  1995-10       Impact factor: 2.680

10.  Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.

Authors:  R P Gleason; L S Schneider
Journal:  J Clin Psychiatry       Date:  1990-03       Impact factor: 4.384

View more
  11 in total

Review 1.  Psychotropic medication use for behavioral symptoms of dementia.

Authors:  Philip S Wang; M Alan Brookhart; Soko Setoguchi; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

2.  Psychotic symptoms in the elderly.

Authors:  Rebecca W Brendel; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

3.  Curing and caring: the work of primary care physicians with dementia patients.

Authors:  Ester Carolina Apesoa-Varano; Judith C Barker; Ladson Hinton
Journal:  Qual Health Res       Date:  2011-06-17

Review 4.  Antipsychotics for behavioural and psychological problems in elderly people with dementia: a systematic review of adverse events.

Authors:  Marianne B van Iersel; Sytse U Zuidema; Raymond T C M Koopmans; Frans R J Verhey; Marcel G M Olde Rikkert
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review.

Authors:  Timo Grimmer; Alexander Kurz
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 6.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

7.  Treatment strategies in Alzheimer's disease with a focus on early pharmacological interventions.

Authors:  Josef Marksteiner; Reinhold Schmidt
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.

Authors:  Dilip V Jeste; Dan Blazer; Daniel Casey; Thomas Meeks; Carl Salzman; Lon Schneider; Pierre Tariot; Kristine Yaffe
Journal:  Neuropsychopharmacology       Date:  2007-07-18       Impact factor: 7.853

Review 9.  Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.

Authors:  Dallas P Seitz; Sudeep S Gill; Nathan Herrmann; Sarah Brisbin; Mark J Rapoport; Jenna Rines; Kimberley Wilson; Ken Le Clair; David K Conn
Journal:  Int Psychogeriatr       Date:  2012-10-19       Impact factor: 3.878

Review 10.  Management of the behavioral and psychological symptoms of dementia.

Authors:  Elizabeth C Hersch; Sharon Falzgraf
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.